Jeffrey Allen Bailey Sells 4,557 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) Director Jeffrey Allen Bailey sold 4,557 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $8.43, for a total transaction of $38,415.51. Following the transaction, the director now directly owns 13,356 shares in the company, valued at approximately $112,591.08. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Aurinia Pharmaceuticals Trading Down 1.2 %

AUPH opened at $8.28 on Thursday. Aurinia Pharmaceuticals Inc. has a fifty-two week low of $4.71 and a fifty-two week high of $10.05. The company has a market cap of $1.19 billion, a price-to-earnings ratio of -55.20 and a beta of 1.45. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. The firm has a 50 day simple moving average of $7.19 and a 200 day simple moving average of $6.18.

Wall Street Analyst Weigh In

AUPH has been the subject of several recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $10.00 price objective on shares of Aurinia Pharmaceuticals in a report on Monday, September 16th. HC Wainwright restated a “buy” rating and issued a $13.00 target price on shares of Aurinia Pharmaceuticals in a research note on Friday, September 6th. Finally, StockNews.com raised Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, November 8th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $10.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. ProShare Advisors LLC increased its stake in Aurinia Pharmaceuticals by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 34,464 shares of the biotechnology company’s stock valued at $173,000 after buying an additional 2,873 shares during the last quarter. FMR LLC grew its position in shares of Aurinia Pharmaceuticals by 44.8% in the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock valued at $93,000 after purchasing an additional 3,919 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in Aurinia Pharmaceuticals by 10.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 52,747 shares of the biotechnology company’s stock worth $301,000 after buying an additional 4,808 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Aurinia Pharmaceuticals by 15.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 38,952 shares of the biotechnology company’s stock worth $196,000 after purchasing an additional 5,079 shares in the last quarter. Finally, Banque Cantonale Vaudoise boosted its stake in shares of Aurinia Pharmaceuticals by 126.6% in the second quarter. Banque Cantonale Vaudoise now owns 9,684 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 5,410 shares during the period. 36.83% of the stock is owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.